The extent of downregulation across PARPi-treated tumor populations provided early evidence for the importance of loss of end protection in the IDH1-mutant context and further supports the notion that the PARPi sensitivity in IDH-mutant cancers is a consequence of a defect in HDR. The gene discussed is IDH1; the disease is cancer.